New understanding of how big molecules bind will lead to better drugs, synthetic organic... (ccording to the ESF workshop convenor Pr...)

New understanding of how big molecules bind will lead to better drugs, synthetic organic materials

Date:2/21/2008

ccording to the ESF workshop convenor, Professor Anthony Davis from Bristol University in the UK. But the most important aspect of the ESF workshop was the bringing together of scientists in two previously distinct fields, said Davis. Our main aim was to get two groups of scientists talking to each other - the supramolecular chemists, and a group of biologists who might be termed biomolecular engineers, said Davis. Certainly this objective was fulfilled. Supramolecular chemists study and manipulate the interactions between molecules in general, while biomolecular engineers specialise in exploiting the large organic molecules found in Nature.

Biological macromolecules include proteins comprising amino acids, complex carbohydrates made from simpler sugar molecules, as well as both RNA and DNA made from nucleic acids. Unlike small molecules, these large constructions exhibit multiple chemical properties at different parts of their surface, which means that interactions between them depend on geometrical features. It is the geometrical arrangement of the component parts, as much as their chemical identity, that determines how a macromolecule will behave and interact with other molecules both large and small. Some molecules will only react or bind with certain others, often temporarily, on a lock and key basis determined by the relative shapes of the surface. Such transient associations between large molecules (supramolecules) are very important in biology, for example in the binding between antibodies and antigens in the immune response, and also between an enzyme and its substrate, i.e. the compound it is acting upon.

These looser interactions between large molecules are called non-covalent because they do not involve sharing of electrons, but instead exploit variations in electrical charge distribution in their vicinity. Since each individual bond is weak, non-covalent bonding relies on the collective strength of multiple bonds and is therefore onl
'/>"/>

Contact: Anthony Davis
Anthony.Davis@bristol.ac.uk
44-117-954-6334
European Science Foundation
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia
2. Bug guts map brings scientists closer to understanding different bugs role in the body
3. Revolution in understanding of ion channel regulation
4. Understanding the have-knots: The role of stress in just about everything
5. OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia
6. Understanding College Student Mental Health: The Psychological, Institutional and Legal Issues
7. Canadian Pacific and Mayo Clinic Build Understanding and Commit to Ongoing Dialogue
8. Understanding of Mammography Differs Among Races
9. Increased Understanding Called for During November National Alzheimers Disease Awareness Month by Los Angeles Jewish Homes Medical Director
10. Optical scientist honored for understanding and improving vision
11. New understanding of basic units of memory

Post Your Comments:

(Date:3/11/2010)... March 11 CoreObjects is ... Management Institutes (PMI) "Excellence Award" for their role ... quality of life for patients suffering from diabetes. ... "Project Management Excellence Award" for their management of ... Sugar Analysis device, designed for diabetes patients. The ...

(Date:3/11/2010)... on skin lesions caused by parasite in Iraq, Afghanistan, ... Heat therapy is effective for treating lesions caused by ... Iraq and Afghanistan, a new study shows. , Since ... American military and civilian personnel have developed Leishmania ... news release about the study. , Naomi Aronson and ...

(Date:3/11/2010)... A research team led by the University of ... cellular "switch" that may provide researchers with a ... with implications for treating cancer. , The new ... programmed cell death, or apoptosis, a cell suicide ... leading to changes like cell body shrinkage, mitochondria ...

(Date:3/11/2010)... testing lab to produce a kit explaining to lawyers how hair alcohol testing works. , ... , ... ... ... Care application orders increased by 46% between April and December last year*, with the number of children ...

(Date:3/11/2010)... Quinn released on March 10, 2010 includes unacceptable cuts to human services ... our state – seniors, people with mental illness and disabilities, victims of violence, and ... across Illinois and further weaken our state,s economy. , ... ... , ...

Breaking Medicine News(10 mins):Health News:CoreObjects Receives Project Management Institutes 'Excellence Award' for Diabetes Contribution 2 Health News:Discovery of cellular 'switch' may provide new means of triggering cell death, treating disease 2 Health News:Discovery of cellular 'switch' may provide new means of triggering cell death, treating disease 3 Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 2 Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 3 Health News:Illinois Budget Cuts Fall Deepest on the Most Vulnerable 2 Health News:Illinois Budget Cuts Fall Deepest on the Most Vulnerable 3

[1] CoreObjects Receives Project Management Institutes 'Excellence Award' for Diabetes Contribution [1] Heat Therapy Helps Treat U.S. Soldiers' Infections [1] Discovery of cellular 'switch' may provide new means of triggering cell death, treating disease [1] Hair Alcohol Test Kit to Help in Third of Care Cases [0] Illinois Budget Cuts Fall Deepest on the Most Vulnerable

... Celebrated Authors, Researchers and Health Professionals Gather at Mental ... on Friday, November 2nd, NEW YORK, Oct. 15 ... 15th Annual Long Island Mental Illness,Awareness Day presented by ... 2, 2007 at the Huntington Hilton in Melville, NY ...

... The Disability Management Employer,Coalition (DMEC), the leading ... absence and disability related employer programs, today,announced ... the growing association.,Michael Klachefsky, Mercer principal and ... Advisory Board effective October 1,2007. "The ...

... ibuprofen and similar medicines pose big stomach risks, study ... Large numbers of patients don,t tell their doctors that ... ibuprofen, a potentially dangerous omission, a new study has ... underreporting their medicine intake, it is no wonder that ...

... of teenagers aged 12-18 claim to have been victims of ... jointly by the University of Haifa and Ben Gurion University. ... the boys and 76% of the girls reported said that ... Prof. Rachel Lev-Wiesel from the University of Haifa,s School of ...

... Benefit More Transplant Patients and Family ... ... (NFT) announced today that it will extend free hotel stays to,more transplant ... through an expansion of its Home Away From,Home program. The Home ...

... Patients with Kidney Impairments - - ... of Patients -, CAMBRIDGE, Mass., Oct. 15 ... announced that the U.S. Food and,Drug Administration (FDA) ... patients with impaired kidney function, including those,requiring dialysis. ...

Other Medicine News:Health News:Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 2 Health News:Disability Management Employer Coalition Names Mercer as Newest Platinum Sponsor 2 Health News:Many Patients Don't Report Use of OTC Pain Drugs 2 Health News:Many Patients Don't Report Use of OTC Pain Drugs 3 Health News:Almost 90 percent of children reported experiencing sexual violence 2 Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 2 Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 3 Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 2 Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 3 Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 4 Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 5 Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 6

Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day Disability Management Employer Coalition Names Mercer as Newest Platinum Sponsor Many Patients Don't Report Use of OTC Pain Drugs Almost 90 percent of children reported experiencing sexual violence National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma

(Date:3/11/2010)... 11 Bayer HealthCare Pharmaceuticals ... has been granted by the U.S. Food ... powder inhaler (DPI) for management of pulmonary ... fibrosis (CF) patients. A similar designation has ... Agency. Ciprofloxacin DPI is an investigational drug–device ...

(Date:3/11/2010)... Ind. , March 11 Zimmer ... a leader in musculoskeletal care, today showcased its recently ... American Academy of Orthopaedic Surgeons (AAOS) annual meeting. The ... the best of Zimmer,s proven hip technologies – ... BIOLOX ® delta and Longevity ® Highly ...

(Date:3/11/2010)... March 11 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) announced today that it has completed its acquisition of 100% ... ... , ... ... ...

Breaking Medicine Technology:FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 2 FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 3 FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 4 FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 5 FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 6 FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 7 FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 8 New Hip Implant Provides Personalized Fit 2 New Hip Implant Provides Personalized Fit 3 New Hip Implant Provides Personalized Fit 4 Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc. 2 Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc. 3 Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc. 4 Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc. 5 New Professional Network Brings Chinese Scientists and Researchers into International Community 59500 1 New Professional Network Brings Chinese Scientists and Researchers into International Community 59500 2 New Professional Network Brings Chinese Scientists and Researchers into International Community 59500 3 New Professional Network Brings Chinese Scientists and Researchers into International Community 59500 4 FIFA Medical Conference 17 and 18 October 2009 in Zurich 59495 1 FIFA Medical Conference 17 and 18 October 2009 in Zurich 59495 2 FIFA Medical Conference 17 and 18 October 2009 in Zurich 59495 3 Press Ganey Partners With Health Management Associates 5494 1 Press Ganey Partners With Health Management Associates 5494 2

[0] FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis [0] New Hip Implant Provides Personalized Fit [0] Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.

... Jude scientists, findings in ataxia telangiectasia-like disease ... the links between brain disease and cancer ... Jan. 14 Scientists at ... apart the biological details distinguishing two related ...

... Jan. 13 MannKind Corporation (Nasdaq: ... trial to demonstrate equivalence of its commercial inhaler to ... clinical trials to deliver AFRESA(TM), MannKind,s ultra rapid acting ... Study 138 - Bioequivalence of Clinical and Commercial Scale ...

Other Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2 Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3 MannKind Reports Successful Completion of Device Bioequivalence Trial 2 MannKind Reports Successful Completion of Device Bioequivalence Trial 3

Study Shows How Defective DNA Repair Triggers Two Neurological Diseases MannKind Reports Successful Completion of Device Bioequivalence Trial

... II system is the Cambridge ... Alternans (MTWA) testing platform which ... cardiac death risk stratification. This ... as it can be configured ...

... highest magnification of ANY gonioscopy lens in existence! ... meshwork. One 62° mirror presents a good ... central portion of the lens can be used ... glaucoma and other central retinal maladies. The extended ...

... Volks Disposable SSV® Vitrectomy Lenses are a ... to enable a view of a particular region ... contact lens element weighs less than 1 gram ... with the typical shape of a human cornea. ...

... Chalam 30° Prism are designed ... are recommended for tractional retinal ... Rhegmatogenus retinal detachment. They can ... and other midperipheral laser applications. ...

Medicine Products:

HearTwave II Microvolt T-Wave Alternans System With Analytic Spectral Method G-1 trabeculum Disposable Vitrectomy Lens Direct Image 30° Prism SSV®

New understanding of how big molecules bind will lead to better drugs, synthetic organic...(ccording to the ESF workshop convenor Pr...),Health